Cytokinetics (CYTK)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 12-2024 | 09-2024 | 06-2024 | 03-2024 | 12-2023 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 94,857 | 46,888 | 190,142 | 119,976 | 113,024 |
| Marketable Securities | 981,157 | 964,804 | 866,633 | 498,985 | 501,800 |
| Receivables | 16,650 | 244 | N/A | 834 | 1,283 |
| TOTAL | $1,107,940 | $1,018,601 | $1,067,810 | $638,704 | $628,051 |
| Non-Current Assets | |||||
| PPE Net | 65,815 | 64,222 | 65,689 | 68,018 | 68,748 |
| Investments And Advances | 145,055 | 269,168 | 305,361 | 15,376 | 40,534 |
| Other Non-Current Assets | 82,863 | 84,069 | 84,928 | 85,984 | 86,983 |
| TOTAL | $293,733 | $417,459 | $455,978 | $169,378 | $196,265 |
| Total Assets | $1,401,673 | $1,436,060 | $1,523,788 | $808,082 | $824,316 |
| Liabilities | |||||
| Current Liabilities | |||||
| Short Term Debt | 11,520 | 11,520 | 11,520 | 11,520 | 10,080 |
| Accounts payable and accrued liabilities | 20,369 | 11,581 | 9,470 | 12,967 | 21,507 |
| Accrued Expenses | 55,323 | 49,826 | 39,813 | 40,123 | 42,641 |
| Other current liabilities | 21,114 | 18,029 | 23,467 | 6,015 | 10,559 |
| TOTAL | $179,674 | $109,812 | $102,777 | $88,855 | $102,678 |
| Non-Current Liabilities | |||||
| Long Term Debt | 93,227 | 93,017 | 92,831 | 56,822 | 58,384 |
| Deferred Revenues | 52,370 | N/A | N/A | N/A | N/A |
| Other Non-Current Liabilities | 1,264,144 | 1,247,142 | 1,219,630 | 1,058,565 | 1,049,577 |
| TOTAL | $1,357,371 | $1,340,159 | $1,312,461 | $1,115,387 | $1,107,961 |
| Total Liabilities | $1,537,045 | $1,449,971 | $1,415,238 | $1,204,242 | $1,210,639 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 118,411 | 118,014 | 117,660 | 104,854 | 103,005 |
| Common Shares | 118 | 118 | 117 | 105 | 102 |
| Retained earnings | -2,701,764 | -2,551,744 | -2,391,199 | -2,247,881 | -2,112,238 |
| Other shareholders' equity | 2,398 | 5,387 | -1,022 | -539 | -10 |
| TOTAL | $-135,372 | $-13,911 | $108,550 | $-396,160 | $-386,323 |
| Total Liabilities And Equity | $1,401,673 | $1,436,060 | $1,523,788 | $808,082 | $824,316 |